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Abstract 
Aims: We aimed to compare characteristics of patients with hyperglycemic hyperosmolar state 
(HHS) and patients with severe hyperglycemia without the signs of hyperosmolarity and 
ketoacidosis; to analyze long-term all-cause mortality and potential prognostic factors. 
Methods: The studied population included 261,749 adults. HHS was diagnosed in patients with 
plasma glucose >33.0 mmol/L, ketonuria <1+, and serum osmolarity >320 mmol/L. Patients with 
plasma glucose >33.0 mmol/L, ketonuria <1+ and serum osmolarity <320 mmol/L were used as 
controls (nHHS). 
Results: During the 5-year period, we observed 68 episodes of HHS in 66 patients and 51 
patients with nHHS. Patients with HHS were significantly older, had lower BMI, higher serum 
C-reactive protein and used diuretics and benzodiazepines more frequently. Mortality rates one, 
three and 12 months after admission were 19.0%, 32.1% and 35.7% in the HHS group, and 
4.8%, 6.3% and 9.4% in the nHHS group (P<0.001). However, after adjustment for patient age, 
these differences were not statistically significant. In multivariate Cox regression in HHS group, 
mortality was positively associated with age, male gender, leukocyte count, amylase, presence of 
dyspnea and somnolence, and the use of benzodiazepines, ACE inhibitors and sulphonylureas, 
while it was inversely associated with plasma glucose, bicarbonate, and the use of thiazides and 
statins. A nomogram derived from these variables had an accuracy of 89% in predicting lethal 
outcome.  
Conclusions: Infection, use of diuretics and benzodiazepines may be important precipitating 
factors of HHS. Prospective clinical trials are mandatory to analyze the safety of ACE-inhibitors 
and benzodiazepines in elderly patients with diabetes. 
 Key words: Diabetes mellitus type 2, hyperglycemic hyperosmolar state, mortality, angiotensin-
converting enzyme inhibitors, benzodiazepines; precipitating factors 
 1. Introduction 
Hyperglycemic hyperosmolar state (HHS) is a life-threatening acute hyperglycemic complication 
that mostly occurs in elderly patients with type 2 diabetes mellitus (DM) 1. However, there is 
some overlap with diabetic ketoacidosis in adults 2, and it can occur in pediatric patients with 
type 2 diabetes 3. The exact pathophysiology is unknown, but severe insulin resistance and 
underlying chronic kidney disease play an important role 4. The true incidence of HHS is 
unknown because population-based studies have not been conducted. Based on data on annual 
discharges of HHS in the United States, it is estimated that HHS affects approximately 1 of 500 
patients with DM and the overall incidence of HHS is less than 1 case per 1000 person-years 5. 
Previous studies have reported that HHS occurs more commonly in elderly female patients, with 
the majority of patients having newly diagnosed DM and infection as the leading precipitating 
factor 1,2,6–9. Inpatient mortality rates are reported to be between 10-40% 1,2,6–9.      
Studies have found that prognostic factors for HHS include age, altered mental status, the 
presence of cardiovascular comorbidities, serum blood nitrogen, sodium, pH, and bicarbonates 
1,2,6–11. However, the majority of studies analyzed only inpatient mortality, and data on the 
prognostic accuracy of these variables are lacking. 
The aim of this population-based, case-control study was to: compare the characteristics of 
patients with HHS and patients with severe hyperglycemia without signs of hyperosmolarity and 
ketoacidosis; analyze long-term all-cause mortality and detect potential prognostic factors.   
 
 
2. Methods 
2.1. Study protocol 
This was a population-based, cross-sectional, cohort study performed in the emergency 
department of a teaching hospital. We reviewed electronic charts from all patients with plasma 
glucose (PG) >33.0 mmol/L at admission between January 1st 2010 and December 31st 2014. 
HHS was defined as PG >33.0 mmol/L, ketonuria <1+ and serum osmolarity >320 mmol/L. 
Patients with PG >33.0 mmol/L, ketonuria <1+ and serum osmolarity <320 mmol/L were used as 
controls (nHHS). 
We analyzed the following parameters: general anthropometric characteristics (age, gender, 
hospitalization and place of residency); signs and symptoms (weight loss, polyuria and 
polydipsia, increased body temperature, vomiting, abdominal pain, dyspnea, mental status 
changes and electrocardiograms); medication (angiotensin-converting-enzyme [ACE] inhibitors, 
calcium channel antagonists, beta-blockers, furosemide, thiazide diuretics, statins, 
antipsychotics, benzodiazepines, sulfonylureas, metformin, insulin and alcohol consumption). 
Diabetes-specific data including body mass index (BMI) and duration of diabetes was obtained 
by searching other institutional electronic registries. Medical doctors were responsible for 
reviewing all electronic charts. All-cause mortality data were obtained from the Croatian 
Department of Public Health. 
 
2.2. Statistical analyses 
Patient characteristics were assessed using descriptive statistics presented as a mean with 
standard deviation. Continuous variables were compared with Mann-Whitney test and 
categorical variables with Fisher exact test. Cox proportional hazard models were used to 
analyze the link between patient characteristics and mortality. Backward conditional stepwise 
approach was used to determine variables independently associated with survival. Stepwise 
conditional backward Cox regression was performed separately in each group of variables: signs 
and symptoms (weight loss, polyuria and polydipsia, increased body temperature, vomiting, 
abdominal pain, dyspnea, mental status and electrocardiograms); general anthropometric 
characteristics and laboratory findings (age, gender, place of residency and laboratory findings); 
medication (ACE inhibitors, calcium channel antagonists, beta-blockers, furosemide, thiazide 
diuretics, statins, antipsychotics, benzodiazepines, sulfonylureas, metformin, insulin and alcohol 
consumption). A nomogram was constructed in the form of a regression equation based on 
unstandardized correlation coefficients derived from the final step of stepwise conditional 
backward Cox regression. Receiver operating characteristic (ROC) analysis was performed in 
order to determine the sensitivity, specificity and positive likelihood ratio of the nomogram in 
predicting all-cause mortality. P values <0.05 were considered significant. The statistical analysis 
was done using SPSS Version 20.0. 
3. Results 
3.1. Patient characteristics 
A total of 68 episodes of HHS occurred in 66 patients. HHS was rare in patients younger than 60 
years, although three patients younger than 60 were diagnosed with HHS. 
Patients with HHS had a median age of 79 (74-86) and 44.1% (30/68) were males. When 
compared with patients with nHHS, patients with HHS were significantly older and had lower 
BMIs (Table 1). The proportion of patients with newly diagnosed DM was lower in the HHS 
group. Consequently, a greater proportion of patients with HHS used oral antidiabetic agents and 
insulin. As expected, patients with HHS had higher serum glucose, blood nitrogen, creatinine, 
sodium, and lower base excess. Although patients with HHS had higher rates of altered mental 
status, altered mental status occurred in only 26.5% of patients. Patients with HHS had higher 
rates of ECG abnormalities, while those with nHHS reported polyuria and weight loss more 
frequently. Interestingly, more patients in the HHS group used benzodiazepines, which may be a 
precipitating factor in some patients (Table 1). 
3.2. Mortality  
After a median follow-up of 24.0 (1.3–36.0) months, 31 patients (46.9%) in the HHS group died. 
Mortality rates one, three and 12 months after admission were 19.0%, 32.1% and 35.7% in the 
HHS group, and 4.8%, 6.3% and 9.4% in the NHHS group, respectively (P<0.001 for all 
comparisons). Patients with HHS had a higher chance of lethal outcome (HR 2.35, 95% CI 1.23–
4.50, P=0.010), especially within the first three months after admission (Figure 1). However, 
after adjustment for patient age, these differences were not statistically significant (HR 1.77, 
95% CI 0.89–3.51, P=0.103). 
In the HHS group, all-cause mortality was positively associated with age, male gender, leukocyte 
count, amylase, presence of dyspnea and somnolence, and the use of benzodiazepines, ACE 
inhibitors and sulphonylureas. On the other hand, it was inversely associated with plasma 
glucose, bicarbonate, and the use of thiazides and statins. In the nHHS group, all-cause mortality 
was positively associated with blood nitrogen, sodium, base excess, and the use of 
sulphonylureas, while it was inversely associated with age, hemoglobin, bicarbonate, and CRP 
(Table 2).  
Therefore, we constructed a nomogram for patients with HHS in the form of a regression 
equation: age × 0.079 + male gender × 0.945 – PG × 0.058 + leukocytes × 0.058 + serum 
amylase × 0.003 – serum bicarbonates × 0.094  - thiazides × 2.793 - statins × 1.910 + 
benzodiazepines × 1.350 + ACE inhibitors × 2.483 + sulphonylureas × 1.891 + dyspnea × 1.191. 
The nomogram had an area under the curve (AUC) of 0.893 (95% CI 0.767–1.000) in predicting 
mortality (Figure 2). A score of >4.03 had a sensitivity of 91.7% (61.5–99.8) and a specificity of 
78.6% (49.2–95.3), with a positive predictive value of 4.3 (1.5–11.8). 
4. Discussion 
Our study revealed several new and interesting points that we would like to discuss. In our 
predominantly Caucasian population, HHS was more common in males, which is similar to 
reports from an Asian population 7. When compared to patients with nHHS, the prevalence of 
newly diagnosed DM was substantially lower in patients with HHS, which is contradictory to 
previous studies 11. We did not perform a specific analysis of precipitating causes of HHS for 
several reasons. First of all, the diagnosis of infection is hard to make in this subgroup of 
patients. Elderly patients may often be afebrile, even in the presence of acute infection. 
Moreover, leukocyte count in patients with HHS may be increased due to dehydration and 
hyperosmolarity. CRP levels may also be increased due to chronic kidney disease, which is also 
prevalent in these patients 12. Moreover, approximately 25% of patients with HHS had altered 
mental status; therefore, information on therapy adherence may be unreliable.  
Our study was the first to analyze medication use in patients with HHS. The prevalence of 
furosemide and benzodiazepine use was substantially higher in patients with HHS. This is an 
important observation because both may be predisposing factors for HHS. A few case reports of 
HHS precipitated by diuretic use have been described 13. Although antipsychotics and 
antidepressants are well known precipitators of both HHS and diabetic ketoacidosis 14, little is 
known about the role of benzodiazepines in these clinical entities. Benzodiazepines are 
associated with a number of adverse effects including daytime sedation and slowed psychomotor 
performance 15, both of which may predispose to dehydration, progression of kidney disease, and 
eventually HHS. 
Mortality rates in our study were exceedingly high, especially within the first three months after 
admission. Although the overall differences in mortality were not statistically significant after 
adjustment for age, these differences were different within the first year of follow-up. As 
reported in previous studies, advanced age, male gender, high glucose, high leukocyte count, low 
bicarbonates, and altered mental status were associated with increased mortality. In addition to 
the previously established prognostic factors, we found that high serum amylase and the presence 
of dyspnea at admission were independently associated with mortality. A nonspecific increase in 
serum amylase is often seen in patients with diabetic ketoacidosis and correlates well with the 
rate of dehydration, hyperosmolarity, and acidosis 16. However, an independent association 
between serum amylase and mortality is a novel finding, which needs to be validated in future 
studies. The presence of dyspnea may correlate with metabolic acidosis and renal and heart 
failure, which are all well-known adverse prognostic factors. In our opinion, the most important 
finding of our study is the association between thiazide and statin use with lower mortality and 
the association between benzodiazepines, ACE inhibitors, and sulphonylureas with increased 
mortality. Although thiazide diuretics are associated with glucose intolerance and increase the 
risk for diabetes 17, they reduce cardiovascular mortality in patients with diabetes 18. In our study, 
a history of thiazide use was associated with an 80% reduction in all-cause mortality. The link 
between statins and decreased mortality is well known, and in our study statin use was associated 
with a 20% reduction in all-cause mortality. The fact that benzodiazepines use was associated 
with a 4-fold increase in mortality in patients with HHS is a novel finding. This can be explained 
by the previously mentioned daytime sedation and slowed psychomotor performance, both of 
which can predispose to dehydration and progression of kidney disease. Previous studies have 
found increased mortality in sulphonylurea users19, so the fact that their use in patients with HHS 
was associated with a 6-fold increase in all-cause mortality could be expected. The most striking 
finding of our study was the 12-fold increase in all-cause mortality in patients with HHS that 
used ACE inhibitors. ACE inhibitors decrease overall mortality in patients with diabetes 20. 
However, ACE inhibitors may induce acute renal failure in some patients 21. A study by Shin et 
al. analyzed urinary atrial natriuretic peptide-like immunoreactivity and plasma atrial natriuretic 
peptide concentration in patients with hyperosmolar-hyperglycemic nonketotic syndrome 
(HHNS). The study showed that urinary atrial natriuretic peptide-like immunoreactivity was 
significantly increased, whereas plasma atrial natriuretic peptide concentration was decreased in 
the face of raised plasma renin activity in HHNS patients. This study indicated that renal atrial 
natriuretic peptide-like immunoreactivity substances and cardiac atrial natriuretic peptide may 
have different responsiveness in diabetic patients with HHS 22. These findings may explain why 
ACE inhibitors exhibit different effects in patients with HHS, which was not observed in patients 
nHHS. 
In the end, we would like to emphasize that our study is the first to report the prognostic 
accuracy of a nomogram in patients with HHS. Our nomogram had 90% accuracy in predicting 
mortality, which could be useful in clinical practice. However, future validation studies are 
needed. 
In conclusion, patients with HHS have higher CRP levels and leukocyte count suggesting that 
infection is a common precipitating factor. The increased use of diuretics and benzodiazepines 
among elderly patients with DM may predispose them to develop HHS. We found that thiazides 
and statins were associated with decreased mortality, and benzodiazepines, ACE inhibitors and 
sulphonylureas were associated with increased mortality. Prospective clinical trials are 
mandatory to analyze the safety of these agents in elderly patients with diabetes. 
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Table 1. Characteristics of the study population divided based on the presence of hyperglycemic 
hyperosmolar syndrome (HHS) 
 nHHS (A) 
N=51 
HHS (B) 
N=68 
Age (years) 68 (55-80) 79 (74-86) A 
Male gender  % (n) 49.0 (25) 44.1 (30) 
Duration of DM (years) 10.0 (0.-19.0) 10.4 (7.0-15.0) 
BMI (kg/m2) 28.1 (23.6-31.1) 25.6 (23.0-28.3) A 
Rural residency % (n) 41.2 (21) 42.4 (28) 
Newly diagnosed DM % (n) 37.5 (18) 8.2 (5) A 
Glucose (mmol/L) 36.8 (34.6-39.9) 39.9 (36.1-46.5) A 
Leukocytes (109/L) 9.7 (7.5-12.6) 12.9 (8.8-18.2) A 
Hemoglobin (g/L) 137.0 (126.0-144.0) 135.0 (126.0-147.0) 
Serum nitrogen (mmol/L) 9.9 (7.9-13.6) 22.1 (13.4-32,4) A 
Creatinin (μmol/L) 129.0 (107.0-165.0) 201.5 (157.0-250.5) A 
Sodium (mmol/L) 128.0 (123.0-131.0) 133.0 (131.0-138.0) A 
Potassium (mmol/L) 4.5 (4.0-4.9) 4.5 (4.2-5.2) 
Amylase (U/L) 38.5 (25.5-57.5) 46.0 (26.0-80.0) 
CRP (mg/L) 14.5 (4.3-101.9) 39.3 (11.6-117.5) 
AST (U/L) 18.5 (14.0-30.0) 19.0 (14.5-32.5) 
ALT (U/L) 24.0 (15.0-41.0) 20.5 (14.0-34.0) 
Capillary blood Ph 7.42 (7.37-7.45) 7.40 (7.32-7.43) 
Base excess (mmol/L) -1.7 (-6.1-1.8) -4.8 (-9.9-(-0.3)) A 
Bicarbonates (mmol/L) 20.7 (16.5-22.9) 17.7 (14.7-22.2) 
Osmolarity (mmol/L) 312.5 (306.9-316.6) 336.1 (325.8-363.3) A 
Abdominal pain % (n) 9.8 (5) 5.9 (4) 
Vomiting % (n) 3.9 (2) 13.2 (9) 
Dyspnea % (n) 9.8 (5) 19.1 (13) 
Febrile % (n) 3.9 (2) 16.1 (11) 
Polyuria % (n) 45.1 (23) 22.1 (15) A 
Weight loss % (n) 15.7 (8) 2.9 (2) A 
Somnolence % (n) 0.0 (0) 16.2 (11) A 
Sopor % (n) 2.0 (1) 8.8 (6) 
Coma % (n) 2.0 (1) 1.5 (1) 
Arrhitmia % (n) 17.6 (9) 39.7 (27) A 
Thiazide diuretic % (n) 9.8 (5) 23.5 (16) 
Fursemide % (n) 19.6 (10) 35.3 (24) 
Antipsychotics % (n) 9.8 (5) 11.8 (8) 
Benzodiazepines % (n) 3.9 (2) 20.6 (14) A 
Betablockers % (n) 27.5 (14) 44.0 (30) 
ACE inhibitors % (n) 33.3 (17) 51.5 (35) 
Insulin therapy % (n) 9.8 (5) 32.4 (22) A 
Metformin % (n) 5.9 (3) 22.1 (15) A 
Sulphonylureas % (n) 13.7 (7) 42.6 (29) A 
Alcohol % (n) 9.8 (5) 7.4 (5) 
A – significant when compared with patients with nHHS 
 Table 2. Results of stepwise conditional backward Cox regression in patients with HHS and 
nHHS, showing independent predictors of all-cause mortality. 
 
 B SE HR 95% CI for HR P 
HHS       
Age .079 .023 1.082 1.034 1.132 .001 
Male gender .945 .457 2.573 1.050 6.307 .039 
Plasma glucose -.058 .026 .944 .896 .994 .028 
Leukocyte count .058 .028 1.059 1.003 1.119 .037 
Amylase .003 .001 1.003 1.001 1.006 .016 
Bicarbonates -.094 .035 .911 .851 .974 .007 
Dyspnea 1.191 .489 3.291 1.262 8.581 .015 
Somnolence .826 .291 2.284 1.290 4.043 .005 
Thiazides -2.793 .762 .061 .014 .272 .000 
Statins -1.910 .872 .148 .027 .818 .028 
Benzodiazepines 1.350 .649 3.859 1.081 13.776 .038 
ACE inhibitors 2.483 .607 11.980 3.647 39.349 .000 
Sulphonylureas 1.891 .543 6.623 2.285 19.198 .000 
nHHS       
Age -.117 .056 .890 .797 .992 .036 
Hemoglobin -.113 .035 .893 .834 .956 .001 
Serum nitrogen .748 .275 2.112 1.231 3.622 .007 
Sodium .990 .328 2.693 1.417 5.117 .002 
CRP -.018 .009 .982 .965 .999 .043 
Base excess .912 .342 2.491 1.274 4.868 .008 
Bicarbonates -1.374 .492 .253 .096 .664 .005 
Sulphonylureas 2.331 .983 10.287 1.497 70.682 .018 
B – unstandardised correlation coefficient; SE – standard error; HR – hazard ratio; CI – 
confidence interval;  
Figure 1. Kaplan-Meier curves showing cumulative hazard between patients with hypergylcemic 
hyperosmolar syndrom (full line) and those with severe hyperglycemia without the signs of 
hyperosmolarity (interrupted line). 
Figure 2. ROC curve showing the diagnostic performance of nomogram in predicting all-cause 
mortality in patients with hyperglycemic hyperosmolar syndrome.   
 
 
  
 
 
